Cardinal Health Announces Spin-Off of Clinical and Medical Products Businesses

DUBLIN, Ohio -- Cardinal Health, a global provider of healthcare products and services, today announced plans for a tax-free spin-off of its clinical and medical products businesses as a separate public company that will be led by current vice chairman and med-tech industry veteran David L. Schlotterbeck.

As a result of the spin-off, which is anticipated to be completed by the middle of calendar year 2009, both companies are expected to benefit from enhanced management focus and sharper strategic vision, as well as better alignment of management and employee incentives with performance and growth objectives. In addition, both companies expect improved opportunities to access and allocate capital, and the ability to make investments in their respective growth areas.

The company also announced that chairman and CEO R. Kerry Clark will continue to lead Cardinal Health through the spin-off and then will retire from the company. Clark will be succeeded by George S. Barrett, who has served as vice chairman and CEO of Healthcare Supply Chain Services since joining Cardinal Health in January.  Barrett has more than 25 years of experience in the healthcare industry, most recently serving as president and CEO of North America for Teva Pharmaceuticals and as a member of Teva’s Office of the CEO.  In addition to his responsibility for North American operations, he led Teva’s global pharmaceutical strategy. 

“Since 1996, Cardinal Health has built an industry-leading med-tech business that, as an independent company, would have the size and scale to stand on its own,” said Clark.  “This business will be well positioned to deliver maximum value to customers and shareholders over the long term. We undertook a very disciplined exploratory process that involved our board, management and outside advisers.  The result was a unanimous decision to move forward with the spin-off.  This strategic decision will benefit Cardinal Health and the new med-tech company by allowing each business to focus on its unique growth strategies, capital needs and customer requirements.

Clark continued, “The substantial strategic and operational steps we have taken put us in the very competitive and enviable market positions we have today. I believe our customers, employees and shareholders will benefit from our ability to be even more focused, and I look forward to leading the effort to complete the spin-off.”

In addition, the company announced that founder Robert D. Walter will retire from its board of directors by not standing for re-election when his term expires on Nov. 5, following the company’s 2008 annual meeting of shareholders. He will continue to serve as an adviser to the company. “I am fully supportive of our plans to spin off the clinical and medical products businesses and am confident that the two businesses will be well positioned as separate companies,” Walter said.  “With strong teams in place to lead these two organizations, my retirement from the board is the next logical step in my leadership transition at Cardinal Health.”

The spin-off of the clinical and medical products businesses will create a new, global company headquartered in San Diego, with industry-leading offerings for infusion, medication and supply dispensing, respiratory care, infection prevention, medical diagnostics and surgical procedures. Products will include the Alaris® IV infusion and Pyxis® dispensing systems, AVEA and LTV® series ventilators, V. Mueller® surgical instruments, and clinically differentiated offerings to reduce hospital-acquired infections through MedMined™ services and ChloraPrep® preoperative skin preparation. Fiscal 2009 pro forma revenue for these businesses as a stand-alone entity is expected to be more than $4 billion, which would place the independent company among the largest medical-technology firms globally.

Schlotterbeck joined Cardinal Health in 2004 through the $2 billion acquisition of Alaris Medical Systems where he was president and CEO.  Prior to Alaris, he was president and chief operating officer of Pacific Scientific Company; president and CEO of Vitalcom, Inc. and executive vice president and chief operating officer of Nellcor, Inc.  He currently serves as vice chairman and CEO of Clinical and Medical Products for Cardinal Health.

Dwight Winstead, currently group president of Clinical and Medical Products, will be named chief operating officer, reporting to Schlotterbeck. An external search has been launched to select a chief financial officer for the new medical-technology company.

Jeffrey W. Henderson will remain chief financial officer of Cardinal Health, a position he has held since 2005, and will report to Barrett after the spin-off. In addition, Michael A. Lynch and Michael C. Kaufmann will be named to senior business leader positions within Cardinal Health.

The proposed tax-free spin-off will be accomplished through a pro rata distribution to Cardinal Health shareholders. Completion of the spin-off is subject to final approval by Cardinal Health’s board of directors, confirmation of the tax-free nature of the transaction, as well as effectiveness of a Form 10 registration statement to be filed with the U.S. Securities and Exchange Commission (SEC). The Form 10 is expected to be filed during the company’s fiscal third quarter (January to March 2009) and will include detailed information about the new medical-technology company, the spin-off and related matters. The company will distribute an information statement to shareholders following completion of the SEC’s review of the Form 10.  Approval by the company’s shareholders is not required for completion of the spin-off. Both companies are expected to be well capitalized to provide financial flexibility to take advantage of future growth opportunities. They are expected to have financial policies, balance sheets and credit metrics that are commensurate with investment-grade credit ratings. 

Cardinal Health will reassess its capital deployment targets as it refines the capital structure of both companies. Share repurchases for this year are expected to total no more than the amount required to offset dilution from issuances for equity compensation. Cardinal Health also expects to continue its regular $0.14 quarterly dividend until the spin-off is completed and anticipates that it will continue to pay a dividend after the spin-off. It is not currently anticipated that the new medical-technology company will pay regular dividends. The company expects that Cardinal Health historical financial statements, adjusted for the spin-off, will be available toward the middle of calendar 2009.

For the current fiscal 2009, the company reiterated guidance it provided on Aug. 7 for revenue growth of 6 percent to 7 percent and non-GAAP diluted EPS from continuing operations2 to be in a range of $3.80 to $3.95. Non-GAAP EPS in the first quarter is still expected to be around $0.70, with EPS returning to more normal levels in the second quarter and overall results stronger in the second half of the year.  The company’s guidance does not reflect any incremental costs it will incur associated with the spin-off and separation of the two companies. The company expects a significant portion of these costs will be classified as special items in accordance with company practices.

Source: Cardinal Health

 

 

 

 

 

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish